Anagram & Information om | Engelska ordet CLL

Exempel på hur man kan använda CLL i en mening

• Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell).
• He was nominated for the post of Chief of the Defence Staff but never held the office because he was suddenly discovered to be terminally ill with Chronic Lymphocytic Leukaemia (CLL).
• Secondary to another disease, such as an antecedent upper respiratory tract infection, systemic lupus erythematosus or a malignancy, such as chronic lymphocytic leukemia (CLL).
• Chlorambucil, sold under the brand name Leukeran among others, is a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma.
• Idelalisib in combination with rituximab showed favourable progression free survival in a phase III clinical trial for chronic lymphocytic leukemia (CLL) compared with patients that received rituximab and placebo.
• Braunias has won more than 40 national awards for writing, including the 2009 Buddle Findlay Sargeson Literary fellowship, the 2010 CLL Non-Fiction Award and the 2006 Qantas Fellowship – the supreme award – at the New Zealand Qantas Media Awards (Print).
• BTK is important for the survival and proliferation of leukemic B cells, which motivated efforts to develop BTK inhibitors as treatments for B cell malignancies such as mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).
• Having identified his limited-over batting as an area he wanted to improve on (he scored only 67 runs in five matches) he decided to play for Monton & Weaste CC in the Central Lancashire League (CLL) during the Caribbean's off-season (summer 2008 in England).
• Since CD19 is a marker of B cells, the protein has been used to diagnose cancers that arise from this type of cell - notably B cell lymphomas, acute lymphoblastic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
• Ofatumumab (Arzerra 100 mg or 1000 mg concentrate for solution for infusion) is indicated for the treatment of untreated, relapsed, or refractory chronic lymphocytic leukemia (CLL).
• Chiorazzi and his colleagues have demonstrated that: CLL cells are responsive to the signals from the internal microenvironment, specifically, those delivered by the B-cell antigen receptor (BCR) leading to leukemic cell proliferation and maturation or death; BCR-induced signals are likely delivered by common self-antigens and are mediated through sets of BCRs of remarkably similar amino acid structure; patients with CLL segregate into two subgroups based on BCR structure that differ dramatically in the clinical outcome; CLL cells proliferate and die in vivo at rates higher than originally appreciated.
• BTK is an important signalling molecule of the B-cell antigen receptor (BCR) pathway, which plays a role in the pathogenesis of several B-cell malignancies including mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and chronic lymphocytic leukemia (CLL).
• In the phase II study, abexinostat showed a modest overall response rate (ORR) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with a notably higher ORR observed in patients with follicular lymphoma.
• Thompson's work with Stanley Korsmeyer establishing the existence of three classes of Bcl-2-related proteins and defining their role in apoptosis led to the development of ABT-263 (navitoclax) and ABT-199 (venetoclax), recently FDA-approved for certain patients with chronic lymphocytic leukemia (CLL).
• In the EU, venetoclax monotherapy is indicated for the treatment of chronic lymphocytic leukemia (CLL) in the presence of 17p deletion or TP53 mutation in adults who are unsuitable for or have failed a B cell receptor pathway inhibitor and for the treatment of CLL in the absence of 17p deletion or TP53 mutation in adults who have failed both chemoimmunotherapy and a B cell receptor pathway inhibitor.
• In the European Union, acalabrutinib as monotherapy or in combination with obinutuzumab is indicated for the treatment of adults with previously untreated chronic lymphocytic leukaemia (CLL).
• It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).
• Furthermore, the company withdrew the pending Biologics License Application (BLA) and supplemental New Drug Application (sNDA) for the treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL) which utilized umbralisib in tandem with ublituximab, known as the "U2" regimen.
• HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL).
• Initially, Slavin pioneered the use of monoclonal antibodies anti-CD52 (Alemtuzumab, now approved by FDA as Lemtrada) for prevention of graft-vs-host disease (GVHD), the most serious complication of allogeneic stem cell transplantation, and later on for treatment of CLL and multiple sclerosis.

Förberedelsen av sidan tog: 179,97 ms.